Synthesis of Flavokawain Analogues and their Anti-neoplastic Effects on Drug-resistant Cancer Cells Through Hsp90 Inhibition
作者:Young Ho Seo、Sun You Park
DOI:10.5012/bkcs.2014.35.4.1154
日期:2014.4.20
Hsp90 is an ubiquitous molecular chaperone protein, which plays an important role in regulating maturation and stabilization of many oncogenic proteins. Due to its potential to simultaneously disable multiple signaling pathways, Hsp90 represents great promise as a therapeutic target of cancer. In this study, we synthesized flavokawain analogues and evaluated their biological activities against drug-resistant cancer cells. The study indicated that compound 1i impaired the growth of gefitinib-resistant non-small cell lung cancer (H1975), down-regulated the expression of Hsp90 client proteins including EGFR, Her2, Met, Akt and Cdk4, and upregulated the expression of Hsp70. The result strongly suggested that compound 1i inhibited the proliferation of cancer cells through Hsp90 inhibition. Overall, compound 1i could serve as a potential lead compound to overcome the drug resistance in cancer chemotherapy.
Hsp90是一种普遍存在的分子伴侣蛋白,在调节多种致癌蛋白的成熟和稳定中起着重要作用。由于其同时禁用多个信号通路的潜力,Hsp90作为癌症的治疗靶点具有巨大前景。在本研究中,我们合成了黄卡瓦醇类似物,并评估了它们对耐药癌细胞的生物活性。研究表明,化合物1i损害了吉非替尼耐药的非小细胞肺癌(H1975)的生长,下调了包括EGFR、Her2、Met、Akt和Cdk4在内的Hsp90客户蛋白的表达,并上调了Hsp70的表达。结果强烈表明,化合物1i通过抑制Hsp90抑制了癌细胞的增殖。总的来说,化合物1i有可能作为一种潜在的先导化合物,克服癌症化疗中的药物耐药性。